September 3, 5.30 pm | Online
Por Dr. Patrick Raber,Senior Manager on the Research and Business Development Team
Dr. Paul Fields, Computational biologist at immunoSEQ Data.
In partnership with Microsoft, Adaptive Biotechnologies has created a comprehensive and detailed open access database, ImmuneCODE, that provides COVID-19 data to accelerate ongoing efforts to develop better diagnostics, vaccines, and therapeutics for COVID-19. Here we present an overview of Adaptive Biotechnologies’ immunoSEQ Technology, including our new immunoSEQ® T-MAP™ COVID service, the use of robust statistical analyses for COVID-19 data, and how you can easily use the immunoSEQ Analyzer to analyze and visualize your immunosequencing COVID-19 data and integrate it with the ImmuneCODE data to gain meaningful insights.
What You Will Learn
- Better understand the principles of Adaptive Biotechnologies’ quantitative immunoSEQ Technology and how it is used to answer immunological research questions.
- Learn about Adaptive Biotechnologies’ ImmuneCODE initiative and how the results can be applied to research using the immunoSEQ T-MAP COVID service
- Understand the broad range of immunosequencing statistics that can be used to assess quantitative characteristics of the immune repertoire, in particular how it pertains to infectious disease and vaccine research.
- Understand how you can easily use the immunoSEQ Analyzer to analyze and visualize your immunosequencing data and integrate it with the ImmuneCODE COVID-19 Data to gain meaningful insights.
